Physician profile
Amanda E Berry
NPI 1083651079
$2,245.78
in general payments reported to CMS, 2019-2025
23 companies · $658 in 2025
The $658 reported for 2025 was more than what 81% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $12.37 · 2023: $556 · 2024: $857 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,070.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $349.47 | 2023-2025 | Ozempic, Rybelsus, Sogroya |
| Abbott Laboratories | $316.23 | 2023-2024 | Aveir, Jot Dx |
| Heartflow, INC. | $290.92 | 2023-2024 | Ffrct |
| Boston Scientific Corporation | $267.81 | 2021-2025 | Watchman Access System, Embold Fibered |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $168.60 | 2024-2025 | Lifevest |
| Cvrx, INC. | $123.56 | 2023-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $109.46 | 2024 | Farxiga |
| Scpharmaceuticals INC. | $95.00 | 2023 | |
| Amgen INC. | $90.24 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $86.49 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $53.36 | 2024-2025 | Camzyos |
| Abiomed | $49.47 | 2024-2025 | Impella |
| Cequr Corporation | $43.04 | 2023-2024 | Cequr Simplicity |
| Philips North America LLC | $34.61 | 2025 | Ecc Solutions |
| Regeneron Healthcare Solutions, INC. | $25.09 | 2024 | Evkeeza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $20.82 | 2025 | Assure Wcd |
| Astellas Pharma US INC | $20.33 | 2023 | Veozah |
| Impulse Dynamics (USA) INC. | $19.08 | 2023 | Optimizer |
| Recordati_rare_diseases_inc. | $18.11 | 2024 | Signifor Lar, Isturisa |
| Abbvie INC. | $17.15 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.14 | 2023 | Unithroid |
| Esperion Therapeutics, INC. | $16.61 | 2025 | Nexletol |
| Horizon Therapeutics Plc | $13.19 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.